Review



s pneumoniae atcc 700669  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    ATCC s pneumoniae atcc 700669
    S Pneumoniae Atcc 700669, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 320 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s+pneumoniae+klein+chester/Streptococcus+pneumoniae+(Klein)+Chester/pm42308351-351-1-3
    Average 96 stars, based on 320 article reviews
    s pneumoniae atcc 700669 - by Bioz Stars, 2026-10
    96/100 stars

    Images

    Related Articles

    Bacteria:

    Article Title: Selection of DNA aptamers to Streptococcus pneumonia and fabrication of graphene oxide based fluorescent assay.
    Article Snippet: Pneumococci are one of the leading causes of infections throughout the world causing problems mainly in children, elderly, and immune-deficient patients.. In recent years antibiotic resistant Streptococcus pneumoniae strains become widespread.. Therefore simple, rapid, and specific detection methods are needed for public health.

    Selection:

    Article Title: Selection of DNA aptamers to Streptococcus pneumonia and fabrication of graphene oxide based fluorescent assay.
    Article Snippet: Pneumococci are one of the leading causes of infections throughout the world causing problems mainly in children, elderly, and immune-deficient patients.. In recent years antibiotic resistant Streptococcus pneumoniae strains become widespread.. Therefore simple, rapid, and specific detection methods are needed for public health.



    Similar Products

    s pneumoniae atcc 700669  (ATCC)
    96
    ATCC s pneumoniae atcc 700669
    S Pneumoniae Atcc 700669, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s+pneumoniae+klein+chester/Streptococcus+pneumoniae+(Klein)+Chester/pm42308351-351-1-3
    Average 96 stars, based on 1 article reviews
    s pneumoniae atcc 700669 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    s pneumoniae atcc 700905  (ATCC)
    94
    ATCC s pneumoniae atcc 700905
    S Pneumoniae Atcc 700905, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s+pneumoniae+klein+chester/Streptococcus+pneumoniae+(Klein)+Chester/pm42284150-242-38-40
    Average 94 stars, based on 1 article reviews
    s pneumoniae atcc 700905 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    reference strain s pneumoniae atcc 49619  (ATCC)
    99
    ATCC reference strain s pneumoniae atcc 49619
    Effects of azeliragon on the in vitro growth of S. pneumoniae . Dose–response relationships of S. pneumoniae <t>ATCC</t> <t>49619</t> (A) , S. pneumoniae 1057 (B) , and S. pneumoniae 1044 (C) following treatment with increasing concentrations of azeliragon. Bacterial growth was measured after 18 h of incubation and expressed as OD 600 . Effects of azeliragon on the growth kinetics of S. pneumoniae ATCC 49619 (D) , S. pneumoniae 1057 (E) , and S. pneumoniae 1044 (F) . Bacteria were cultured under control conditions or with different concentrations of azeliragon, and OD 600 was recorded at indicated time points to generate growth curves. Data were presented as mean ± SD. The experiments were performed with three independent biological replicates ( n = 3). “ns” represented no significant difference, ** p < 0.01.
    Reference Strain S Pneumoniae Atcc 49619, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s+pneumoniae+klein+chester/Streptococcus+pneumoniae+(Klein)+Chester/pmc13102591-151-11-15
    Average 99 stars, based on 1 article reviews
    reference strain s pneumoniae atcc 49619 - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    reference genome s pneumoniae atcc 700669  (ATCC)
    96
    ATCC reference genome s pneumoniae atcc 700669
    Effects of azeliragon on the in vitro growth of S. pneumoniae . Dose–response relationships of S. pneumoniae <t>ATCC</t> <t>49619</t> (A) , S. pneumoniae 1057 (B) , and S. pneumoniae 1044 (C) following treatment with increasing concentrations of azeliragon. Bacterial growth was measured after 18 h of incubation and expressed as OD 600 . Effects of azeliragon on the growth kinetics of S. pneumoniae ATCC 49619 (D) , S. pneumoniae 1057 (E) , and S. pneumoniae 1044 (F) . Bacteria were cultured under control conditions or with different concentrations of azeliragon, and OD 600 was recorded at indicated time points to generate growth curves. Data were presented as mean ± SD. The experiments were performed with three independent biological replicates ( n = 3). “ns” represented no significant difference, ** p < 0.01.
    Reference Genome S Pneumoniae Atcc 700669, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s+pneumoniae+klein+chester/Streptococcus+pneumoniae+(Klein)+Chester/bio_rxiv__64898__2026__04__03__714713-72-45-49
    Average 96 stars, based on 1 article reviews
    reference genome s pneumoniae atcc 700669 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    s pneumoniae atcc 700669 reference genome  (ATCC)
    96
    ATCC s pneumoniae atcc 700669 reference genome
    Effects of azeliragon on the in vitro growth of S. pneumoniae . Dose–response relationships of S. pneumoniae <t>ATCC</t> <t>49619</t> (A) , S. pneumoniae 1057 (B) , and S. pneumoniae 1044 (C) following treatment with increasing concentrations of azeliragon. Bacterial growth was measured after 18 h of incubation and expressed as OD 600 . Effects of azeliragon on the growth kinetics of S. pneumoniae ATCC 49619 (D) , S. pneumoniae 1057 (E) , and S. pneumoniae 1044 (F) . Bacteria were cultured under control conditions or with different concentrations of azeliragon, and OD 600 was recorded at indicated time points to generate growth curves. Data were presented as mean ± SD. The experiments were performed with three independent biological replicates ( n = 3). “ns” represented no significant difference, ** p < 0.01.
    S Pneumoniae Atcc 700669 Reference Genome, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s+pneumoniae+klein+chester/Streptococcus+pneumoniae+(Klein)+Chester/pm41885611-80-8-10
    Average 96 stars, based on 1 article reviews
    s pneumoniae atcc 700669 reference genome - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    s pneumoniae  (ATCC)
    99
    ATCC s pneumoniae
    Dose‐dependent bactericidal effect of curcumin‐mediated (PDI) against S. <t>pneumoniae</t> (A) and S. pyogenes (B). Bacterial viability is expressed as log₁₀ CFU/mL following exposure to increasing concentrations of curcumin (0.25–5.0 µM) under a fixed light dose (6.4 J/cm 2 ). Different letters above the bars indicate statistically significant differences among groups; the same letter indicates they are equal (one‐way ANOVA followed by Tukey's test, p < 0.05). Bars represent the mean ± standard deviation of three independent experiments.
    S Pneumoniae, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s+pneumoniae+klein+chester/Streptococcus+pneumoniae+(Klein)+Chester/pmc13074127-39-2-7
    Average 99 stars, based on 1 article reviews
    s pneumoniae - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    s pneumoniae atcc 700904  (ATCC)
    99
    ATCC s pneumoniae atcc 700904
    Effects of consecutive photodynamic inactivation (PDI) cycles on the minimum inhibitory concentration (MIC) of amoxicillin (AMO) using two different light doses. Panels show MIC values for S. pneumoniae <t>ATCC</t> <t>700904</t> after PDI with light doses of 6.4 J/cm 2 (A) and 12.8 J/cm 2 (B), and for S. pyogenes after PDI with light doses of 6.4 J/cm 2 (C) and 12.8 J/cm 2 (D). Breakpoint values established by BRCAST are included to highlight interpretive thresholds for bacterial resistance.
    S Pneumoniae Atcc 700904, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s+pneumoniae+klein+chester/Streptococcus+pneumoniae+(Klein)+Chester/pmc13074127-97-2-4
    Average 99 stars, based on 1 article reviews
    s pneumoniae atcc 700904 - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Effects of azeliragon on the in vitro growth of S. pneumoniae . Dose–response relationships of S. pneumoniae ATCC 49619 (A) , S. pneumoniae 1057 (B) , and S. pneumoniae 1044 (C) following treatment with increasing concentrations of azeliragon. Bacterial growth was measured after 18 h of incubation and expressed as OD 600 . Effects of azeliragon on the growth kinetics of S. pneumoniae ATCC 49619 (D) , S. pneumoniae 1057 (E) , and S. pneumoniae 1044 (F) . Bacteria were cultured under control conditions or with different concentrations of azeliragon, and OD 600 was recorded at indicated time points to generate growth curves. Data were presented as mean ± SD. The experiments were performed with three independent biological replicates ( n = 3). “ns” represented no significant difference, ** p < 0.01.

    Journal: Frontiers in Medicine

    Article Title: Protective effects of the RAGE inhibitor azeliragon as a potential anti- Streptococcus pneumoniae therapeutic in sepsis models

    doi: 10.3389/fmed.2026.1793580

    Figure Lengend Snippet: Effects of azeliragon on the in vitro growth of S. pneumoniae . Dose–response relationships of S. pneumoniae ATCC 49619 (A) , S. pneumoniae 1057 (B) , and S. pneumoniae 1044 (C) following treatment with increasing concentrations of azeliragon. Bacterial growth was measured after 18 h of incubation and expressed as OD 600 . Effects of azeliragon on the growth kinetics of S. pneumoniae ATCC 49619 (D) , S. pneumoniae 1057 (E) , and S. pneumoniae 1044 (F) . Bacteria were cultured under control conditions or with different concentrations of azeliragon, and OD 600 was recorded at indicated time points to generate growth curves. Data were presented as mean ± SD. The experiments were performed with three independent biological replicates ( n = 3). “ns” represented no significant difference, ** p < 0.01.

    Article Snippet: To further assess the effects of azeliragon on pneumococcal growth, the reference strain S. pneumoniae ATCC 49619 and two clinical isolates (1057 and 1044) were examined under different drug concentrations.

    Techniques: In Vitro, Incubation, Bacteria, Cell Culture, Control

    Time-kill activity and biofilm disruption effects of azeliragon against S. pneumoniae . Time-kill curves of S. pneumoniae ATCC 49619 (A) , S. pneumoniae 1057 (B) , and S. pneumoniae 1044 (C) treated with azeliragon (4× MIC). Bacteria were cultured under control conditions or treated with azeliragon (4× MIC) or vancomycin (4× MIC), and viable counts (CFU/mL) were determined at indicated time points. Effects of azeliragon (4× MIC) on biofilm biomass of S. pneumoniae ATCC 49619 (D) , S. pneumoniae 1057 (E) , and S. pneumoniae 1044 (F) . Mature biofilms were treated with the indicated drugs for 24 h and quantified by crystal violet staining. Results are expressed as OD₅₇₀. Data were presented as mean ± SD. Data were presented as mean ± SD. The experiments were performed with six independent biological replicates ( n = 6). Group comparisons for biofilm assays were analyzed by one-way ANOVA followed by Tukey’s multiple-comparison test. “ns” represented no significant difference, *** p < 0.001.

    Journal: Frontiers in Medicine

    Article Title: Protective effects of the RAGE inhibitor azeliragon as a potential anti- Streptococcus pneumoniae therapeutic in sepsis models

    doi: 10.3389/fmed.2026.1793580

    Figure Lengend Snippet: Time-kill activity and biofilm disruption effects of azeliragon against S. pneumoniae . Time-kill curves of S. pneumoniae ATCC 49619 (A) , S. pneumoniae 1057 (B) , and S. pneumoniae 1044 (C) treated with azeliragon (4× MIC). Bacteria were cultured under control conditions or treated with azeliragon (4× MIC) or vancomycin (4× MIC), and viable counts (CFU/mL) were determined at indicated time points. Effects of azeliragon (4× MIC) on biofilm biomass of S. pneumoniae ATCC 49619 (D) , S. pneumoniae 1057 (E) , and S. pneumoniae 1044 (F) . Mature biofilms were treated with the indicated drugs for 24 h and quantified by crystal violet staining. Results are expressed as OD₅₇₀. Data were presented as mean ± SD. Data were presented as mean ± SD. The experiments were performed with six independent biological replicates ( n = 6). Group comparisons for biofilm assays were analyzed by one-way ANOVA followed by Tukey’s multiple-comparison test. “ns” represented no significant difference, *** p < 0.001.

    Article Snippet: To further assess the effects of azeliragon on pneumococcal growth, the reference strain S. pneumoniae ATCC 49619 and two clinical isolates (1057 and 1044) were examined under different drug concentrations.

    Techniques: Activity Assay, Disruption, Bacteria, Cell Culture, Control, Staining, Comparison

    In vivo protective effects of azeliragon in a mouse infection model. (A) Determination of the infectious dose of S. pneumoniae 1044. (B) Therapeutic efficacy of azeliragon in the pneumonia model. (C) Seven-day survival curves of mice with sepsis induced by S. pneumoniae ATCC 49619. Mice received vehicle control, bacterial control, azeliragon (5 mg/kg or 10 mg/kg), or vancomycin (10 mg/kg). Each group contained 10 mice. Survival was monitored continuously. (D) Seven-day survival curves of mice with sepsis induced by the clinical S. pneumoniae isolate 1044. Experimental groups and treatments were identical to those in (A) . Survival data were plotted using the Kaplan–Meier method, and statistical significance was determined using the log-rank (Mantel–Cox) test. “ns” represented no significant difference, * p < 0.05, ** p < 0.01, and *** p < 0.001.

    Journal: Frontiers in Medicine

    Article Title: Protective effects of the RAGE inhibitor azeliragon as a potential anti- Streptococcus pneumoniae therapeutic in sepsis models

    doi: 10.3389/fmed.2026.1793580

    Figure Lengend Snippet: In vivo protective effects of azeliragon in a mouse infection model. (A) Determination of the infectious dose of S. pneumoniae 1044. (B) Therapeutic efficacy of azeliragon in the pneumonia model. (C) Seven-day survival curves of mice with sepsis induced by S. pneumoniae ATCC 49619. Mice received vehicle control, bacterial control, azeliragon (5 mg/kg or 10 mg/kg), or vancomycin (10 mg/kg). Each group contained 10 mice. Survival was monitored continuously. (D) Seven-day survival curves of mice with sepsis induced by the clinical S. pneumoniae isolate 1044. Experimental groups and treatments were identical to those in (A) . Survival data were plotted using the Kaplan–Meier method, and statistical significance was determined using the log-rank (Mantel–Cox) test. “ns” represented no significant difference, * p < 0.05, ** p < 0.01, and *** p < 0.001.

    Article Snippet: To further assess the effects of azeliragon on pneumococcal growth, the reference strain S. pneumoniae ATCC 49619 and two clinical isolates (1057 and 1044) were examined under different drug concentrations.

    Techniques: In Vivo, Infection, Drug discovery, Control

    Dose‐dependent bactericidal effect of curcumin‐mediated (PDI) against S. pneumoniae (A) and S. pyogenes (B). Bacterial viability is expressed as log₁₀ CFU/mL following exposure to increasing concentrations of curcumin (0.25–5.0 µM) under a fixed light dose (6.4 J/cm 2 ). Different letters above the bars indicate statistically significant differences among groups; the same letter indicates they are equal (one‐way ANOVA followed by Tukey's test, p < 0.05). Bars represent the mean ± standard deviation of three independent experiments.

    Journal: Lasers in Surgery and Medicine

    Article Title: Targeting the Dynamic Susceptibility Window: Time‐Sensitive Photodynamic Synergy With Antibiotics Against Streptococcus spp

    doi: 10.1002/lsm.70116

    Figure Lengend Snippet: Dose‐dependent bactericidal effect of curcumin‐mediated (PDI) against S. pneumoniae (A) and S. pyogenes (B). Bacterial viability is expressed as log₁₀ CFU/mL following exposure to increasing concentrations of curcumin (0.25–5.0 µM) under a fixed light dose (6.4 J/cm 2 ). Different letters above the bars indicate statistically significant differences among groups; the same letter indicates they are equal (one‐way ANOVA followed by Tukey's test, p < 0.05). Bars represent the mean ± standard deviation of three independent experiments.

    Article Snippet: Strains of S. pneumoniae (American Type Culture Collection—ATCC 49619 and ATCC 700904) and a clinical isolate of S. pyogenes obtained from a patient with pharyngotonsillitis were selected for the study.

    Techniques: Standard Deviation

    Time‐kill curves of S. pneumoniae (A) and S. pyogenes (B) following exposure to the antimicrobials: amoxicillin (AMO—0.25 and 16,384 μg/mL), erythromycin (ERY—0.25 μg/mL), and ceftriaxone (CEF—0.25 and 4 μg/mL), with the respective concentrations applied for each bacterial species.

    Journal: Lasers in Surgery and Medicine

    Article Title: Targeting the Dynamic Susceptibility Window: Time‐Sensitive Photodynamic Synergy With Antibiotics Against Streptococcus spp

    doi: 10.1002/lsm.70116

    Figure Lengend Snippet: Time‐kill curves of S. pneumoniae (A) and S. pyogenes (B) following exposure to the antimicrobials: amoxicillin (AMO—0.25 and 16,384 μg/mL), erythromycin (ERY—0.25 μg/mL), and ceftriaxone (CEF—0.25 and 4 μg/mL), with the respective concentrations applied for each bacterial species.

    Article Snippet: Strains of S. pneumoniae (American Type Culture Collection—ATCC 49619 and ATCC 700904) and a clinical isolate of S. pyogenes obtained from a patient with pharyngotonsillitis were selected for the study.

    Techniques:

    Survival of S. pneumoniae (log CFU/mL) over time (h) following treatment. Panels A and D show the effects of amoxicillin (AMO), B and E ceftriaxone (CEF), and C and F erythromycin (ERY). Photodynamic inactivation (PDI) with curcumin (CUR) was applied at 2.5 μM (panels A–C) and 0.5 μM (panels D–F) as a subsequent treatment.

    Journal: Lasers in Surgery and Medicine

    Article Title: Targeting the Dynamic Susceptibility Window: Time‐Sensitive Photodynamic Synergy With Antibiotics Against Streptococcus spp

    doi: 10.1002/lsm.70116

    Figure Lengend Snippet: Survival of S. pneumoniae (log CFU/mL) over time (h) following treatment. Panels A and D show the effects of amoxicillin (AMO), B and E ceftriaxone (CEF), and C and F erythromycin (ERY). Photodynamic inactivation (PDI) with curcumin (CUR) was applied at 2.5 μM (panels A–C) and 0.5 μM (panels D–F) as a subsequent treatment.

    Article Snippet: Strains of S. pneumoniae (American Type Culture Collection—ATCC 49619 and ATCC 700904) and a clinical isolate of S. pyogenes obtained from a patient with pharyngotonsillitis were selected for the study.

    Techniques:

    Effects of consecutive photodynamic inactivation (PDI) cycles on the minimum inhibitory concentration (MIC) of amoxicillin (AMO) using two different light doses. Panels show MIC values for S. pneumoniae ATCC 700904 after PDI with light doses of 6.4 J/cm 2 (A) and 12.8 J/cm 2 (B), and for S. pyogenes after PDI with light doses of 6.4 J/cm 2 (C) and 12.8 J/cm 2 (D). Breakpoint values established by BRCAST are included to highlight interpretive thresholds for bacterial resistance.

    Journal: Lasers in Surgery and Medicine

    Article Title: Targeting the Dynamic Susceptibility Window: Time‐Sensitive Photodynamic Synergy With Antibiotics Against Streptococcus spp

    doi: 10.1002/lsm.70116

    Figure Lengend Snippet: Effects of consecutive photodynamic inactivation (PDI) cycles on the minimum inhibitory concentration (MIC) of amoxicillin (AMO) using two different light doses. Panels show MIC values for S. pneumoniae ATCC 700904 after PDI with light doses of 6.4 J/cm 2 (A) and 12.8 J/cm 2 (B), and for S. pyogenes after PDI with light doses of 6.4 J/cm 2 (C) and 12.8 J/cm 2 (D). Breakpoint values established by BRCAST are included to highlight interpretive thresholds for bacterial resistance.

    Article Snippet: Strains of S. pneumoniae (American Type Culture Collection—ATCC 49619 and ATCC 700904) and a clinical isolate of S. pyogenes obtained from a patient with pharyngotonsillitis were selected for the study.

    Techniques: Concentration Assay

    Effects of consecutive photodynamic inactivation (PDI) cycles on the minimum inhibitory concentration (MIC) of amoxicillin (AMO) using two different light doses. Panels show MIC values for S. pneumoniae ATCC 700904 after PDI with light doses of 6.4 J/cm 2 (A) and 12.8 J/cm 2 (B), and for S. pyogenes after PDI with light doses of 6.4 J/cm 2 (C) and 12.8 J/cm 2 (D). Breakpoint values established by BRCAST are included to highlight interpretive thresholds for bacterial resistance.

    Journal: Lasers in Surgery and Medicine

    Article Title: Targeting the Dynamic Susceptibility Window: Time‐Sensitive Photodynamic Synergy With Antibiotics Against Streptococcus spp

    doi: 10.1002/lsm.70116

    Figure Lengend Snippet: Effects of consecutive photodynamic inactivation (PDI) cycles on the minimum inhibitory concentration (MIC) of amoxicillin (AMO) using two different light doses. Panels show MIC values for S. pneumoniae ATCC 700904 after PDI with light doses of 6.4 J/cm 2 (A) and 12.8 J/cm 2 (B), and for S. pyogenes after PDI with light doses of 6.4 J/cm 2 (C) and 12.8 J/cm 2 (D). Breakpoint values established by BRCAST are included to highlight interpretive thresholds for bacterial resistance.

    Article Snippet: In contrast, S. pneumoniae ATCC 700904 was resistant to all three antibiotics, with MICs of 4 μg/mL (AMO), 16 μg/mL (ERY), and 2 μg/mL (CEF), respectively.

    Techniques: Concentration Assay